Atul Bioscience's Ambernath Plant Passes FDA Inspection with Zero Findings
Atul Bioscience's Ambernath plant passes FDA inspection with zero findings, receives EIR.
The United States Food and Drug Administration (USFDA) provided Atul Bioscience Ltd with an establishment inspection report (EIR) for its manufacturing plant located in Ambernath, Maharashtra.
Following the facility's most recent inspection, which took
place from May 6–10, 2024, and resulted in zero FDA 483 findings, the EIR was
released.The company's activities include contract manufacturing, intermediate
production, and the production and commercialisation of active medicinal
ingredients.
"The successful completion of this inspection reflects
the dedication and hard work of our entire team," stated Dr. Prabhakar
Chebiyyam, Managing Director of ABL.
It fortifies our determination to continually provide
pharmaceutical goods of the highest calibre and to further enhance our
procedures in order to satisfy the constantly changing demands of the world
pharmaceutical market."
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion